Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4D | Q08499 | 2/20 | 0.43 |
| ▸ | HTR2A | P28223 | 1/20 | 0.37 |
| ▸ | HTR2C | P28335 | 1/20 | 0.37 |
| ▸ | HTR2B | P41595 | 1/20 | 0.37 |
| ▸ | SCN9A | Q15858 | 14/20 | 0.36 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.34 |
| ▸ | ACACB | O00763 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23088650 | 0.84 | PDE4D (0.40) | PDE4D | |
| SCHEMBL30712009 | 0.84 | PDE4D (0.40) | PDE4D | |
| SCHEMBL30712010 | 0.83 | DRD2 (0.32) | HTR2ALIPG | |
| SCHEMBL23088633 | 0.83 | DRD2 (0.32) | HTR2ALIPG | |
| SCHEMBL23088644 | 0.80 | PDE4D (0.65) | PDE4DHTR2AHTR2CHTR2BSCN9A | |
| SCHEMBL23088646 | 0.80 | PDE4D (0.65) | PDE4DHTR2AHTR2CHTR2BSCN9A | |
| SCHEMBL30712006 | 0.80 | PDE4D (0.65) | PDE4DHTR2AHTR2CHTR2BSCN9A | |
| SCHEMBL21130412 | 0.76 | PDE4D (0.44) | PDE4DHTR2AHTR2CHTR2BSCN9A | |
| SCHEMBL30712013 | 0.76 | PDE4D (0.44) | PDE4DHTR2AHTR2CHTR2BSCN9A | |
| SCHEMBL23088635 | 0.76 | PDE4D (0.59) | PDE4DSCN9ALIPG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11384096-B2 | Substituted azetidine dihydrothienopyridines and their use as phosphodiesterase inhibitors | UNION therapeutics A/S (DK) | 2022-07-12 | — | — | US | disclosed |
| US-20210079012-A1 | SUBSTITUTED AZETIDINE DIHYDROTHIENOPYRIDINES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | UNION therapeutics A/S (DK) | 2021-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11384096-B2 | Substituted azetidine dihydrothienopyridines and their use as phosphodiesterase inhibitors | PDE2A, PDE3A, PDE3B | PDE4D 12/4885HTR2A 500/4885HTR2C 1187/4885 |
| US-20210079012-A1 | SUBSTITUTED AZETIDINE DIHYDROTHIENOPYRIDINES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | PDE2A, PDE3A, PDE3B | PDE4D 12/4885HTR2A 500/4885HTR2C 1187/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.